Wedbush Reiterates Outperform Rating for Vor Biopharma (NYSE:VOR) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for.
Q1 2024 EPS Estimates for Vor Biopharma Inc (NYSE:VOR) Reduced by Wedbush theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Wedbush reiterated their outperform rating on shares of Vor Biopharma (NYSE:VOR – Free Report) in a research report report published on Thursday, Benzinga reports. They currently have a $11.00 price target on the stock. Wedbush also issued estimates for Vor Biopharma’s Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 […]
JMP Securities Reaffirms Market Outperform Rating for Vor Biopharma (NYSE:VOR) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.